SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending due to its highly anticipated earnings report, with community discussion polarized between expectations of surging AI revenue and concerns over high valuation and potential post-earnings sell-offs mirroring other recent tech reports.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is surging as a substantial patent settlement removes a major legal overhang, while the FDA's reversal to review its flu vaccine application is driving bullish sentiment and sparking community talk of a massive short squeeze, with attention now turning to its promising oncology pipeline.

Okta, Inc. engages in the provision of an identity management platform for enterprises. It operates through the United States and International geographical segments. The firm's products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Okta is actively trending following its latest earnings report, which, despite an earnings and revenue beat with raised guidance, saw the stock decline due to investor concerns over the lack of fiscal 2027 outlook and broader AI disruption fears within the cybersecurity sector. The community is sharply divided, debating if the sell-off is an overreaction or if the stock will continue its historical underperformance.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending due to escalating geopolitical tensions, which are spotlighting its advanced tactical drone systems, especially the Black Widow, amidst increasing defense sector demand and US Army initiatives. Community discussions center on the anticipation of significant contract awards and a potential short squeeze.

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.

Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals is trending amidst fervent buyout speculation, fueled by recent volume spikes and rumors of potential acquisition by suitors such as Jazz Pharmaceuticals or Ipsen. The community is actively debating a potential takeover, with many believing the company's strong oncology pipeline, including OJEMDA and the Mersana acquisition, and current valuation make it an attractive target in an active M&A market.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini (GEMI) is sparking significant community discussion after securing a CFTC Designated Contract Market license and launching its prediction market, leading to speculation about a short squeeze and its potential to ride a Bitcoin rally, even as past underperformance raises investor skepticism.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com is trending ahead of its Q4 earnings report, with community sentiment largely negative due to sustained underperformance and price declines, even as some investors highlight its low valuation, substantial cash reserves, and strategic competitive advantages within the Chinese e-commerce sector.

BlackRock Institutional Trust Company N.A. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

The iShares MSCI South Korea ETF is highly volatile amid geopolitical concerns that triggered market circuit breakers; however, robust underlying demand for AI-driven memory chips from major holdings like Samsung and SK Hynix is fueling a strong rebound, leading community discussion on whether initial market fear was overblown.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the following segments: B&W Renewable, B&W Environmental, and B&W Thermal. The B&W Renewable segment supports a circular economy, diverting waste from landfills to use for power generation and replacing fossil fuels, while recovering metals and reducing emissions. The B&W Environmental segment focuses on systems for cooling, ash handling, particulate control, nitrogen oxides and sulfur dioxides removal, chemical looping for carbon control, and mercury control. The B&W Thermal segment offers steam generation equipment, aftermarket parts, construction, maintenance, and field services for plants in the power generation, oil and gas, and industrial sectors. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox is trending after securing a $2.4 billion contract to build a 1.2-gigawatt natural gas plant for Applied Digital's AI data centers, a deal widely regarded as transformational given its magnitude relative to the company's market capitalization. The community is actively discussing BW's strong position to rapidly deliver critical power solutions for the booming AI infrastructure, with potential for further substantial projects.

Hydrograph Clean Power, Inc. engages in the research, development, marketing and commercialization of patented technology to produce pristine graphene, graphene derivatives and services. The company was founded by Harold Charles Davidson on June 26, 2017 and is headquartered in Vancouver, Canada.

Hydrograph Clean Power Inc

Hydrograph Clean Power is trending after securing crucial EPA, UK, and EU regulatory clearances, which unlock commercial sales of its pure graphene across major global markets. This development, coupled with an oversubscribed capital raise and upcoming facility ramp-ups, is fueling community excitement for the company's revolutionary material and its vast, multi-sector potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bio-Path Holdings Inc.’s stock (BPTH) soared over 150% Thursday afternoon, hitting levels last seen in August, making it the second-biggest gainer across U.S. exchanges.&nbsp;The surge followed the company’s announcement of promising preclinical data for its drug candidate BP1001-A, targeting obesity and related metabolic disorders in Type 2 diabetes patients.The preclinical studies revealed that BP1001-A enhances insulin sensitivity by downregulating growth factor receptor-bound protein 2 (Grb2), which plays a crucial role in insulin signaling.&nbsp;By targeting Grb2, the treatment demonstrated potential in lowering blood glucose levels. This approach is seen as a promising alternative to current weight loss drugs that struggle to show efficacy in obese patients with Type 2 diabetes.Bio-Path CEO Peter Nielsen said, “The failure of leading weight loss medications to induce weight loss in obese patients who have Type 2 diabetes creates a compelling need for an alternative method of lowering blood glucose in obese patients who have Type 2 diabetes.”"We are excited by the rapid progress we have made advancing BP1001-A as a potential treatment for obesity and related metabolic diseases in Type 2 diabetes patients based on previous BP1001-A preclinical studies as they support our continued and rapid development of this promising program,” he added.The company said it has initiated animal studies to further confirm the drug’s efficacy, with plans to launch a first-in-human Phase 1 trial in 2025.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BPTH_sentiment_and_messahe_volume_Dec_20_4b61c6386d.png" alt="BPTH sentiment and messahe volume Dec 20.png" width="1318" height="324"><figcaption>BPTH sentiment and message volume Dec 20 as of 2:00 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, Bio-Path became a trending symbol, with sentiment turning ‘extremely bullish’ as message volume reached its highest point this year.&nbsp;Many retail investors expressed enthusiasm for accumulating the stock during after-hours trading to counter potential short-seller activity.<stembedurl>https://stocktwits.com/Henry666666/message/597231530</stembedurl><stembedurl>https://stocktwits.com/dpell17/message/597231919</stembedurl><stembedurl>https://stocktwits.com/Trader1141/message/597221863</stembedurl>In October, Bio-Path shares surged after the company announced its development program for BP1001-A. While the drug is being explored for obesity and metabolic diseases, it is also undergoing a Phase 1/1b trial for solid tumors.Despite the dramatic single-day rally, the stock remains down over 80% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market data with uptrend vector | Illustration Source: Getty Images

Bio-Path Rockets To 4-Month High As Obesity Drug Shows Promise For Diabetes: Retail In Celebration Mode

The company said it has initiated animal studies to further confirm the drug’s efficacy, with plans to launch a first-in-human Phase 1 trial in 2025.

Equity

Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1001-A, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

BPTH
Bio-Path Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BPTH News

BPTHBio-Path Holdings Inc